Studies esketamine nasal spray use in people with hard-to-treat depression
Observes esketamine nasal spray use and its effects in adults with treatment-resistant depression.
Plain-language title generated from the registry record
Registry title: Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Key facts
- Where
- Chieti, Genova, Milan, and Pavia, ItalySee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT07146503, who can take part
Where in Italy
- Università di ChietiChieti, ItalyTaking people
- Csm Dds 8Genova, ItalyTaking people
- Ospedale Policlinico San MartinoGenova, ItalyTaking people
- ASST Fatebenefratelli SaccoMilan, ItalyTaking people
- ASST PaviaPavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Riccardo Guglielmo
- Trial code
- NCT07146503
- Record updated
- 31 March 2026
- Original description
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.Read full original descriptionShow less
ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.